Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Trial details
- Registry ID
- NCT02452528
- Phase
- Phase 2
The FDA approved Entecavir (Baraclude) on 29 Mar 2005.
Drug identity checked against registry records
Also recorded as Baraclude
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2005-03-29Day | Entecavir | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021797", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["BARACLUDE"], "active_ingredients": ["ENTECAVIR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20050329", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |